Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2017. The registrant is a foreign private issuer based in Ness Ziona, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is a corporate announcement regarding the expiration of specific tradable options rather than a financial results report.
Material Changes
The filing announces the upcoming expiration of Series 4 tradable options issued by the Company and traded exclusively on the Tel Aviv Stock Exchange (TASE). Key details include:
- Expiration Date: Monday, February 27, 2017.
- Last Trade Day: February 22, 2017.
- Exercise Price: NIS 1.50 per option (approximately $0.398 USD based on the February 1, 2017 exchange rate).
- Consequence: Options not exercised by the expiration date will expire and grant no rights to holders.
Guidance, Outlook, and Risks
The filing clarifies that Series 4 options are not listed for trade on The NASDAQ Capital Market. No management commentary, financial guidance, or discussion of general business risks is included in this specific document.
Investor Verification Checklist
- Verify the current status of Series 4 options (BVXV.W4) on the Tel Aviv Stock Exchange.
- Confirm the final exercise deadline of February 27, 2017, for any held options.
- Check the current exchange rate between NIS and USD to assess the real-time value of the NIS 1.50 exercise price.
- Review the Company's shelf prospectus (references 2012-01-017205 and 2013-01-049656) for full terms of the Series 4 options.